Abbott Laboratories 2012 Annual Report Download - page 25

Download and view the complete annual report

Please find page 25 of the 2012 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

CANCER
NEUROLOGY
HEPATITIS C
VIRUS
3x
6
30%
ongoing phase three
programs
of AbbVie’s
pipeline: biologics
as many NMEs
as 3 years ago
10 compounds or new
indications in mid-stage
development
Including several poised to enter Phase Three
within 18 months.
AbbVie has tripled its number of new molecular
entities (NMEs) in development over the last
several years.
Including several that represent billion-
dollar-plus peak-sales opportunities.
AbbVie’s pipeline is strong and specialty
focused, with approximately one-third
composed of innovative biologics.
23
Abbott 2012 Annual Report